Pancreatitis

Gastroenterology·MeSH: Pancreatitis

Prevalence

79.6 / 100K

Incidence

37.0 / 100K/yr

19 drugs in development·15 companies·1 clinical trial

Drug Pipeline by Phase

Approved(5)

Drug	Company
Creon™	ABBOTT LABORATORIES (ABT)
fenofibrate	Amneal Pharmaceuticals, Inc. (AMRX)
kyslecel	Orgenesis Inc. (ORGS)
linagliptin	Mylan II B.V. (MYL)
ozempic	Novo Nordisk A/S (NVO)

Phase 2(5)

Drug	Company
adrulipase	GridAI Technologies Corp. (GRDX)
cm4620 injectable emulsion	CalciMedica, Inc. (CALC)
Hydrocortisone	Valneva SE (VALN)
Infusion of 10 mg/kg Infliximab	UNITED THERAPEUTICS Corp (UTHR)
Infusion of 5 mg/kg Infliximab	UNITED THERAPEUTICS Corp (UTHR)

Phase 1(1)

Drug	Company
Simvastatin	UNITED THERAPEUTICS Corp (UTHR)

Preclinical(4)

Drug	Company
ALPHA-1062 for acute pancreatitis	Alpha Cognition Inc. (ACOG)
CM6336	CalciMedica, Inc. (CALC)
ltx-608	TALPHERA, INC. (TLPH)
REV102	RECURSION PHARMACEUTICALS, INC. (RXRX)

Phase 1/Phase 2(2)

Drug	Company
cm4620	GH Research PLC (GHRS)
mesenchymal stem cells	GH Research PLC (GHRS)

Phase 2/Phase 3(1)

Drug	Company
dm300	DiaMedica Therapeutics Inc. (DMAC)

Phase 4(1)

Drug	Company
Pancreatic Enzyme Replacement Therapy	Crinetics Pharmaceuticals, Inc. (CRNX)

BioSniper tracks 19 drugs in development for Pancreatitis across 15 companies.

There are 1 clinical trial targeting Pancreatitis tracked by BioSniper.

The estimated prevalence of Pancreatitis is approximately 79.6 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.